The Federal Trade Commission is continuing its fight against alleged anti-competitive behavior in the pharmaceutical industry by pushing for federal legislation barring makers of brand-name prescription drugs from paying generic drug manufacturers to delay a generic drug release, which deprives consumers of affordable prescription drugs. Industry attorneys counter that proposed legislation banning such settlements would prolong patent court fights between generic and brand-name drug makers.
Popularity: 2% [?]
Posted on Friday, February 23rd, 2007. Filed under: Business Law, Law Misc
You can leave a response, or trackback from your own site.